Venoarterial ECMO Without Routine Systemic Anticoagulation Decreases Adverse Events.
Despite limited evidence, systemic anticoagulation is the current standard of care for patients supported on venoarterial extracorporeal membrane oxygenation (VA-ECMO). We hypothesized that not anticoagulating patients on VA-ECMO would decrease complications. We retrospectively reviewed adult VA-ECMO patients at our institution. Patients were stratified based on anticoagulation strategy. The primary outcome was a composite of hemorrhagic and thrombotic complications. Secondary outcomes included blood product utilization, incidence of heparin-induced thrombocytopenia (HIT), hospital length of stay, and in-hospital mortality. From May 2011 through January 2018, there were 203 eligible patients supported on VA-ECMO, 35% (75) were not anticoagulated. Overall complication rates were significantly lower for the no anticoagulation group (57% vs 76%, p=0.007) including a trend toward fewer hemorrhagic complications (53% vs 63%, p=0.178) without increased risk of thrombosis (13% vs 21%, p=0.147). The anticoagulated group required more transfusions of packed red blood cells (12.8 vs 1.09, p=0.002) and platelets (3.0 vs 1.3, p=0.009) and showed a higher incidence of HIT (8% vs 0%, p=0.015). There was no difference in overall mortality (72% vs 62%, p=0.165). The absence of routine systemic anticoagulation for patients supported on VA-ECMO is not associated with higher mortality, pump failure, or thrombotic complications. Patients had a lower requirement for blood product transfusions, and there was no incidence of HIT. VA-ECMO patients without other indications for anticoagulation can be treated without systemic anticoagulation during their VA-ECMO course.